iSPOT-D is the largest biomarker study ever undertaken in major depressive disorder. The aim of this study is to identify genetic, brain and cognitive markers (or combinations of markers) that predict specific response to a range of antidepressants (sertraline, escitalopram, venlafaxine) in patients diagnosed with major depressive disorder (MDD). This ground breaking study, funded by Brain Resource, may change the way in which personalised medicine is implemented in depression.
Family of Depression Study
The aim of this project is to understand vulnerability for depression in individuals. By understanding how depression develops, we can develop prevention and early intervention strategies.
We will investigate a range of contributing factors including genetics, brain, behaviour, personality and experienced symptoms, as well as the impact of life events. We will follow participants up one year after the initial visit to see how the initial measures relate to wellbeing and symptom development overtime. Integration across these measures will contribute to a deeper understanding of the development of depression.